Ticagrelor vs clopidogrel on vein graft patency in patients with diabetes undergoing coronary artery bypass grafting
BACKGROUNDPatients with type 2 diabetes mellitus (T2DM) undergoing coronary artery bypass grafting (CABG) are at high risk of saphenous vein graft (SVG) failure.The optimal antiplatelet therapy for maintaining SVG patency in this population remains uncertain. AIMTo investigate whether ticagrelor plus aspirin is associated with better 5-year SVG patency than clopidogrel plus aspirin in patients with T2DM who undergo CABG. CONCLUSIONAmong 5-year survivors with T2DM who underwent CABG, ticagrelor plus aspirin was associated with better 5-year SVG grade A patency than clopidogrel plus aspirin.This is an uncontrolled observational association, and the estimand is limited to patients who survived to the 5-year CTA.The MACE and BE are inconclusive.These findings do not establish causality, superiority, or equivalent safety.Adequately powered, multicenter, prospective randomized controlled trials are required.
Authors
- Keng Zhong
- Guanxin Zhang (ORCID: https://orcid.org/0000-0003-1064-5323)
- Jiao-Na Qiu
- Qing Xue
- Zhi-Min Zhao
- Jie Lu
- Xing-Li Fan
- Wen-Wen Li
- Rui-Jun Yuan
Institutions
- Second Military Medical University (CN)
- Changhai Hospital (CN)
Publication Details
- Journal
- World Journal of Diabetes
- Published
- 2026-11-18
- DOI
- https://doi.org/10.4239/wjd.125765
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Shanghai Municipal Health Commission
- National Natural Science Foundation of China
- Changhai Hospital of Shanghai